Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes - PubMed (original) (raw)

Review

. 2002 Dec;9(12):1022-35.

doi: 10.1038/sj.cgt.7700542.

Affiliations

• PMID: 12522441
• DOI: 10.1038/sj.cgt.7700542

Review

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

Terry W Hermiston et al. Cancer Gene Ther. 2002 Dec.

Abstract

Oncolytic viruses are attractive therapeutics for cancer because they selectively amplify, through replication and spread, the input dose of virus in the target tumor. To date, clinical trials have demonstrated marked safety but have not realized their theoretical efficacy potential. In this review, we consider the potential of armed therapeutic viruses, whose lytic potential is enhanced by genetically engineered therapeutic transgene expression from the virus, as potential vehicles to increase the potency of these agents. Several classes of therapeutic genes are outlined, and potential synergies and hurdles to their delivery from replicating viruses are discussed.

PubMed Disclaimer

Similar articles

• Replication-selective oncolytic viruses in the treatment of cancer.
  Everts B, van der Poel HG. Everts B, et al. Cancer Gene Ther. 2005 Feb;12(2):141-61. doi: 10.1038/sj.cgt.7700771. Cancer Gene Ther. 2005. PMID: 15472714 Review.
• Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses.
  Bauzon M, Hermiston TW. Bauzon M, et al. Curr Opin Mol Ther. 2008 Aug;10(4):350-5. Curr Opin Mol Ther. 2008. PMID: 18683099 Review.
• Vaccinia virus and oncolytic virotherapy of cancer.
  Thorne SH, Hwang TH, Kirn DH. Thorne SH, et al. Curr Opin Mol Ther. 2005 Aug;7(4):359-65. Curr Opin Mol Ther. 2005. PMID: 16121702 Review.
• Comparison of replication-selective, oncolytic viruses for the treatment of human cancers.
  Wildner O. Wildner O. Curr Opin Mol Ther. 2003 Aug;5(4):351-61. Curr Opin Mol Ther. 2003. PMID: 14513677 Review.
• Oncolytic herpes simplex virus vectors for cancer virotherapy.
  Varghese S, Rabkin SD. Varghese S, et al. Cancer Gene Ther. 2002 Dec;9(12):967-78. doi: 10.1038/sj.cgt.7700537. Cancer Gene Ther. 2002. PMID: 12522436 Review.

Cited by

• Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.
  Sarkar S, Quinn BA, Shen XN, Dash R, Das SK, Emdad L, Klibanov AL, Wang XY, Pellecchia M, Sarkar D, Fisher PB. Sarkar S, et al. Oncotarget. 2015 May 10;6(13):10712-27. doi: 10.18632/oncotarget.3544. Oncotarget. 2015. PMID: 25926554 Free PMC article.
• Theranostic potential of oncolytic vaccinia virus.
  Rojas JJ, Thorne SH. Rojas JJ, et al. Theranostics. 2012;2(4):363-73. doi: 10.7150/thno.3724. Epub 2012 Apr 5. Theranostics. 2012. PMID: 22509200 Free PMC article.
• Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
  Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Kirn DH, et al. PLoS Med. 2007 Dec;4(12):e353. doi: 10.1371/journal.pmed.0040353. PLoS Med. 2007. PMID: 18162040 Free PMC article.
• Oncolytic viruses & their specific targeting to tumour cells.
  Singh PK, Doley J, Kumar GR, Sahoo AP, Tiwari AK. Singh PK, et al. Indian J Med Res. 2012 Oct;136(4):571-84. Indian J Med Res. 2012. PMID: 23168697 Free PMC article. Review.
• Fighting cancer with oncolytic viruses.
  Chernajovsky Y, Layward L, Lemoine N. Chernajovsky Y, et al. BMJ. 2006 Jan 21;332(7534):170-2. doi: 10.1136/bmj.332.7534.170. BMJ. 2006. PMID: 16424499 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database